Fig. 1

Genetic characteristics and signaling pathways of 25 PTL patients through whole-exome sequencing. A The SNV and CNV spectrum of 25 PTL patients, showing the mutation frequency of each gene (right) and the clinical data of each sample (bottom). B Relationship between relapse and TMB in 25 PTL patients. The Kaplan–Meier curves for PFS of 25 PTL patients in TMB (log-rank test, P = 0.032) and the relapse rates in the TMB-high and TMB-low groups (Wilcoxon test, P = 0.01). C CNV profiles on all chromosomes of 25 PTL patients. D Proportion of CNV deletions in each type of HLA. The expression of HLA-A, HLA-C, PD-L1 and PD-L2 between nodal DLBCLs and PTL (Wilcoxon test, HLA-A, P = 0.00955; HLA-C, P = 0.0115; PD-L1, P = 0.118; PD-L2, P = 8e−06). E Pathway analysis of mutational genes in the exome of 25 PTL patients. F A network of genes enriched in three immune-related pathways